TauroPace™

TauroPace™ is certified for use during procedures of placing or revising CIEDs, including: 

• pacemakers (PM) 

• implantable cardioverter defibrillators (ICD)  

• PMs and ICDs able to deliver cardiac resynchronization therapy (CRT-P, CRT-D) 

• cardiac contractility modulation (CCM) 

• subcutaneous ICD (S-ICD) 

• leadless PMs  

• implantable or injectable loop recorders or monitors (ILR/ILM)  

• all respective hardware (generator, leads, torque wrench, dilators, sheaths, wires, etc.)  

• The main active ingredient of TauroPace™ is taurolidine.  

• Taurolidine has a broad antimicrobial activity against all relevant pathogens, including (but not limited to) multi-resistant superbugs (e.g. MRSA, MRSE, Klebsiella, Candida species). 

• no severe adverse device effects (SADE) reported 

• no contraindications known other than pre-existing allergies against taurolidine or polyvinylpyrrolidone (PVP) – either not reported to date 

• 100 ml vials (one vial to be used per patient/procedure) 
• storage at temperatures between 15 °C and 25 °C (do not freeze!) 

Report from European registry 2024

“[TauroPace™] appears to be effective and safe in preventing CIED infections.” 

Vonthein et al. J Cardiothorac Surgery. DOI: 10.1186/s13019-024-03059-1 

BHRS standards 2024

“The antimicrobial agent Tauropace has been used in patients at high risk of infection and registry data shows encouraging results following its use associated with a reduced risk of infection in a prospective observational study. Chlorhexidine pocket lavage in high risk procedures was associated with a reduced risk of infection without adverse events.” 

Standards for implantation and follow-up of cardiac rhythm management devices in adults. British Heart Rhythm Society 2024.  

Clinical study 2023

“TauroPace covered 654 procedures on 631 patients, and H2O2 covered 551 procedures on 532 patients. The TauroPace group had more patient risk factors for infection than the H2O2 group (P = 0.0058) but similar device and procedure-specific risk factors (P = 0.17). Cardiac implantable electronic device infection occurred in 0/654 (0%) of the TauroPace group and 6/551 (1.1%) of the H2O2 group (P = 0.0075). Death occurred in 23/654 (3.5%) of the TauroPace group and 14/551 (2.5%) of the H2O2 group (P = 0.33).” 

Borov et al. EP Europace 2023. DOI: 10.1093/europace/euad306